{"id":223,"date":"2014-03-18T14:12:42","date_gmt":"2014-03-18T18:12:42","guid":{"rendered":"http:\/\/www.gqr-lmc-nmp.ca\/system\/?p=223"},"modified":"2014-05-06T14:13:43","modified_gmt":"2014-05-06T18:13:43","slug":"sante-canada-approuve-conditionnellement-lemploi-de-bosulif","status":"publish","type":"post","link":"https:\/\/www.gqr-lmc-nmp.ca\/system\/2014\/03\/18\/sante-canada-approuve-conditionnellement-lemploi-de-bosulif\/","title":{"rendered":"Sant\u00e9 Canada approuve conditionnellement l&#8217;emploi de BOSULIF"},"content":{"rendered":"<p>Le 18 mars 2014 Sant\u00e9 Canada a \u00e9mis un avis de conformit\u00e9 conditionnel (AC-C) pour BOSULIF (bosutinib) dans le traitement des adultes atteints de leuc\u00e9mie my\u00e9lo\u00efde chronique (LMC) \u00e0 chromosome Philadelphie positif (Ph+) en phase chronique, en phase acc\u00e9l\u00e9r\u00e9e ou en crise blastique qui ont pr\u00e9sent\u00e9 une r\u00e9sistance ou une intol\u00e9rance \u00e0 un traitement pr\u00e9alable par un inhibiteur de tyrosine kinase et pour qui un traitement subs\u00e9quent par l\u2019imatinib, le nilotinib ou le dasatinib n\u2019est pas indiqu\u00e9 d\u2019un point de vue clinique.<\/p>\n<p>Pour plus d&rsquo;information veuillez lire le <a href=\"http:\/\/cmlsociety.org\/wp-content\/uploads\/2014\/03\/Bosulif-NOC-News-Release-Final-French-17-03-14v2.pdf\" target=\"_blank\">communiqu\u00e9 de presse<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 18 mars 2014 Sant\u00e9 Canada a \u00e9mis un avis de conformit\u00e9 conditionnel (AC-C) pour BOSULIF (bosutinib) dans le traitement\u2026<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/223"}],"collection":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/comments?post=223"}],"version-history":[{"count":2,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/223\/revisions"}],"predecessor-version":[{"id":225,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/posts\/223\/revisions\/225"}],"wp:attachment":[{"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/media?parent=223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/categories?post=223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gqr-lmc-nmp.ca\/system\/wp-json\/wp\/v2\/tags?post=223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}